ANIK (Anika Therapeutics Inc) Stock Analysis - Politician Trades

Anika Therapeutics Inc (ANIK) is a publicly traded Healthcare sector company. As of May 21, 2026, ANIK trades at $15.50 with a market cap of $198.92M and a P/E ratio of -19.92. ANIK moved +1.48% today. Year to date, ANIK is +59.87%; over the trailing twelve months it is +26.59%. Its 52-week range spans $7.87 to $25.65. Analyst consensus is buy with an average price target of $17.50. Rallies surfaces ANIK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded ANIK stock?

Rallies tracks politician and congressional stock disclosures for ANIK, including purchases, sales, transaction dates, owners, and reported trade amounts when available.

ANIK Key Metrics

Key financial metrics for ANIK
MetricValue
Price$15.50
Market Cap$198.92M
P/E Ratio-19.92
EPS$-0.76
Dividend Yield0.00%
52-Week High$25.65
52-Week Low$7.87
Volume7
Avg Volume0
Revenue (TTM)$112.82M
Net Income$-10.88M
Gross Margin56.56%

Latest ANIK News

Recent ANIK Insider Trades

  • HENNEMAN JOHN B III bought 5.00K (~$73.32K) on May 1, 2026.
  • Griffin Stephen D. bought 12.20K (~$149.88K) on Apr 30, 2026.

ANIK Analyst Consensus

2 analysts cover ANIK: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $17.50.

Common questions about ANIK

Which politicians traded ANIK stock?
Rallies tracks politician and congressional stock disclosures for ANIK, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in ANIK?
Yes. Rallies tracks politician and congressional stock disclosures for ANIK, including reported purchases, sales, dates, owners, and trade amounts when available.
Is ANIK research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ANIK. It does not provide personalized investment advice.
ANIK

ANIK